Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nkarta Inc (NQ: NKTX )

4.400 +0.140 (+3.29%)
Streaming Delayed Price Updated: 11:04 AM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 236,308
Open 4.270
Bid (Size) 4.390 (4)
Ask (Size) 4.400 (7)
Prev. Close 4.260
Today's Range 4.180 - 4.545
52wk Range 1.810 - 16.24
Shares Outstanding 48,934,928
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Why Nkarta Stock Is Soaring Today
One analyst is now more bullish about this clinical-stage biotech stock. 
Via The Motley Fool

Performance

YTD
-30.93%
-30.93%
1 Month
-15.55%
-15.55%
3 Month
-31.99%
-31.99%
6 Month
-40.46%
-40.46%
1 Year
+139.78%
+139.78%

More News

Read More
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024
Via InvestorPlace
NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024
Via InvestorPlace
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
From Nkarta, Inc.
Via GlobeNewswire
3 Undervalued Stocks Primed for a 2X Return
Via InvestorPlace
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street’s Radar
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Via Benzinga
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Nasdaq Turns Higher; Akanda Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; US New Home Sales Fall In February
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Nkarta Announces Pricing of $240 Million Underwritten Offering
From Nkarta, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.